Diabetic nephropathy is a chronic, degenerative disease of the kidney caused by diabetes.
The kidneys are two bean-shaped organs that extract waste from blood, balance body fluids, form urine, and aid in other important functions of the body. Every day, the two kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine, composed of wastes and extra fluid.
The kidney is not one large filter. Each kidney is made up of about a million filtering units called nephrons. These structures filter your blood, help remove waste from the body, and control fluid balance.
Diabetes can cause the nephrons to thicken and scar, which makes them less able to filter waste and remove fluid from the body. This causes them to leak a type of protein called albumin into your urine, leading to diabetic nephropathy.
There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics) and this population is expected to grow. Patients suffering from diabetic nephropathy progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease. There is a significant unmet medical need for new treatments that can slow or stabilize the progression of diabetic nephropathy.
Pathogenic oxidative chemistries are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy.
Unlike any currently approved therapy, NephroGenex, Inc.'s (NRX) Pyridorin(R) (pyridoxamine dihydrochloride) works by targeting and scavenging a broad range of pathogenic oxidative chemistries that develop in diabetic patients—reducing their numbers and potential for causing irreversible kidney damage.
Completed Phase 2 studies have indicated that Pyridorin is effective in inhibiting this important underlying cause of diabetic nephropathy and slowing its progression, with more than an approximately 50% treatment effect demonstrated in patients with mild to moderate levels of disease, and in patients with advanced disease that were previously on an established stable regimen of standard of care. NRX is now in a Phase 3 study with Pyridorin.
NRX said that it has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase 2 studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.
According to NRX, these study results are important given the concerns over cardiac safety seen with other therapies in development for this disease, and support the use of Pyridorin in patients with diabetic nephropathy, many of whom suffer from cardiovascular disease.
NRX is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries.
More about NephroGenex, Inc. (NRX) at www.nephrogenex.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Bakersfield ( www.bakersfield.crwe-pr.com ), the 9th largest city in California and one of the fastest growing regions in the nation, to the CRWE Network.
Bakersfield relies primarily on agriculture, petroleum extraction and refining, as well as manufacturing as its major economic staples.
The City of Bakersfield had an estimated population in 2013 (U.S. Census Bureau) of 363,630, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
The kidneys are two bean-shaped organs that extract waste from blood, balance body fluids, form urine, and aid in other important functions of the body. Every day, the two kidneys filter about 120 to 150 quarts of blood to produce about 1 to 2 quarts of urine, composed of wastes and extra fluid.
The kidney is not one large filter. Each kidney is made up of about a million filtering units called nephrons. These structures filter your blood, help remove waste from the body, and control fluid balance.
Diabetes can cause the nephrons to thicken and scar, which makes them less able to filter waste and remove fluid from the body. This causes them to leak a type of protein called albumin into your urine, leading to diabetic nephropathy.
There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics) and this population is expected to grow. Patients suffering from diabetic nephropathy progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease. There is a significant unmet medical need for new treatments that can slow or stabilize the progression of diabetic nephropathy.
Pathogenic oxidative chemistries are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy.
Unlike any currently approved therapy, NephroGenex, Inc.'s (NRX) Pyridorin(R) (pyridoxamine dihydrochloride) works by targeting and scavenging a broad range of pathogenic oxidative chemistries that develop in diabetic patients—reducing their numbers and potential for causing irreversible kidney damage.
Completed Phase 2 studies have indicated that Pyridorin is effective in inhibiting this important underlying cause of diabetic nephropathy and slowing its progression, with more than an approximately 50% treatment effect demonstrated in patients with mild to moderate levels of disease, and in patients with advanced disease that were previously on an established stable regimen of standard of care. NRX is now in a Phase 3 study with Pyridorin.
NRX said that it has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase 2 studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.
According to NRX, these study results are important given the concerns over cardiac safety seen with other therapies in development for this disease, and support the use of Pyridorin in patients with diabetic nephropathy, many of whom suffer from cardiovascular disease.
NRX is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries.
More about NephroGenex, Inc. (NRX) at www.nephrogenex.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included Bakersfield ( www.bakersfield.crwe-pr.com ), the 9th largest city in California and one of the fastest growing regions in the nation, to the CRWE Network.
Bakersfield relies primarily on agriculture, petroleum extraction and refining, as well as manufacturing as its major economic staples.
The City of Bakersfield had an estimated population in 2013 (U.S. Census Bureau) of 363,630, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
